Scarica l'app Stockscreener
5.225
0.98%
-0.06
Precedente Chiudi:
$5.285
Aprire:
$5.21
Volume 24 ore:
83,786
Relative Volume:
0.11
Capitalizzazione di mercato:
$286.57M
Reddito:
$124.00K
Utile/perdita netta:
$-49.99M
Rapporto P/E:
-3.0917
EPS:
-1.69
Flusso di cassa netto:
$-31.03M
1 W Prestazione:
+9.71%
1M Prestazione:
+2.81%
6M Prestazione:
-5.71%
1 anno Prestazione:
+6.80%
Intervallo 1D:
$5.20
$5.27
Intervallo di 1 settimana:
$4.38
$5.32
Portata 52W:
$4.25
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Nome
Candel Therapeutics Inc
Settore
Industria
Telefono
617-916-5445
Indirizzo
117 KENDRICK STREET, NEEDHAM
Confronta CADL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
5.22 | 288.77M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.87 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.25 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.98 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
912.98 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.57 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-28 | Iniziato | Stephens | Overweight |
| 2025-09-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-30 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-20 | Iniziato | Citigroup | Buy |
| 2025-02-19 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-07 | Iniziato | BofA Securities | Buy |
| 2022-12-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-08-23 | Iniziato | Credit Suisse | Outperform |
| 2021-08-23 | Iniziato | Jefferies | Buy |
| 2021-08-23 | Iniziato | UBS | Buy |
Mostra tutto
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Candel Therapeutics, Inc. Hosts R&D Day Highlighting Viral Immunotherapy Advances - TradingView
How Candel Therapeutics Inc. stock trades before earningsJuly 2025 Sentiment & AI Driven Stock Price Forecasts - Newser
Is Candel Therapeutics Inc. stock recession proof2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Is Candel Therapeutics Inc. stock attractive after correctionWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
Is Candel Therapeutics Inc. stock resilient to inflationPortfolio Update Summary & Safe Capital Investment Plans - Newser
Candel: lighting the path to a brighter future for patients with solid tumors - Nature
Candel Therapeutics (CADL) Upgraded to Strong Buy: Here's What You Should Know - MSN
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics stock price target raised to $14 by Freedom Capital - Investing.com Nigeria
Will Candel Therapeutics Inc. stock gain from strong economy2025 Price Targets & High Accuracy Trade Alerts - newser.com
What technical models suggest about Candel Therapeutics Inc.’s comebackIndex Update & Safe Entry Zone Tips - newser.com
Why Candel Therapeutics Inc. stock could see breakout soon2025 Earnings Impact & Verified Swing Trading Watchlists - newser.com
How geopolitical tensions affect Candel Therapeutics Inc. stockPortfolio Update Report & Stepwise Trade Signal Guides - newser.com
How Candel Therapeutics Inc. stock performs in stagflationJuly 2025 Earnings & Technical Buy Zone Confirmations - newser.com
Candel Therapeutics Inc. (CADL) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Candel Therapeutics Inc. building a consolidation baseShare Buyback & AI Powered Market Trend Analysis - newser.com
Candel Therapeutics to host virtual Research & Development event - Proactive Investors
Candel Therapeutics, Inc. Announces Virtual Research and Development Day for December 5, 2025 - Quiver Quantitative
Candel Therapeutics to Host Virtual R&D Event on December 5, 2025 - The Manila Times
Candel Therapeutics (Nasdaq: CADL) Sets Virtual R&D Event on Immuno-Oncology, CAN-2409 and CAN-3110 - Stock Titan
Will Candel Therapeutics Inc. stock benefit from automationJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
How Candel Therapeutics Inc. stock compares to growth peersJuly 2025 Highlights & Verified Entry Point Signals - newser.com
What’s next for Candel Therapeutics Inc. stock price2025 Price Action Summary & Safe Entry Zone Tips - newser.com
Will Candel Therapeutics Inc. see short term momentumWeekly Stock Summary & Consistent Profit Trade Alerts - newser.com
Analysts’ Top Healthcare Picks: Candel Therapeutics (CADL), Pfizer (PFE) - The Globe and Mail
Candel Therapeutics Broadens Its Clinical Cancer Studies - Kalkine Media
Citigroup Maintains Candel Therapeutics (CADL) Buy Recommendation - Nasdaq
Candel Therapeutics (CADL) Analyst Rating Update: Citigroup Lowe - GuruFocus
Candel Therapeutics Reports Wider Loss, But Analysts Stay Upbeat - Finimize
Candel pausing development of CAN-2409 in pancreatic cancer type - Seeking Alpha
Candel Therapeutics Inc Azioni (CADL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Candel Therapeutics Inc Azioni (CADL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Nichols William Garrett | Chief Medical Officer |
Jul 28 '25 |
Sale |
6.98 |
937 |
6,540 |
52,493 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Option Exercise |
1.29 |
781 |
1,007 |
53,274 |
| Nichols William Garrett | Chief Medical Officer |
Jun 30 '25 |
Sale |
5.04 |
781 |
3,936 |
52,493 |
0.14%
0.27%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):